# Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects

> **NCT02144714** · PHASE1 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 189 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** SB5
- **BIOLOGICAL:** EU sourced Humira®
- **BIOLOGICAL:** US sourced Humira®

## Key facts

- **NCT ID:** NCT02144714
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02144714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02144714, "Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02144714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*